Log In
Print
BCIQ
Print
Print this Print this
 

dolutegravir (Tivicay)

Also known as: 1349572 (GSK1349572, S/GSK1349572) (formerly S-349572)

  Manage Alerts
Collapse Summary General Information
Company ViiV Healthcare Ltd.
DescriptionHIV integrase inhibitor
Molecular Target HIV integrase
Mechanism of ActionHIV integrase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV infection in patients ages 12 and over; Treat HIV-1 infection; Treat HIV-1 infection in treatment-experienced patients; Treat HIV-1 infection in treatment-naïve patients
Regulatory Designation

U.S. - Priority Review (Treat HIV infection in patients ages 12 and over);
EU - Standard Review (Treat HIV-1 infection);
Japan - Orphan Drug (Treat HIV-1 infection)

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today